Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

General Updates | Targeting CD47 in myelofibrosis

Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, talks on the role of CD47 and CALR in myelofibrosis (MF) and comments on the potential of targeting CD47 in MF. It has been shown that patients with MF overexpress CD47, an anti-phagocytic receptor, and have a lower expression of CALR, a pro-phagocytic molecule, which results in a dominant anti-phagocytic signal. Recent in vitro assays have shown that treatment with ruxolitinib and magrolimab, a monoclonal antibody against CD47, led to increased cell death. This interview took place virtually.